Clinical trial · no report yet · Phase 2
ILUSTRO
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
- NCT03505320 ↗
- Active not recruiting
- Astellas Pharma Global Development, Inc.
- 61 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 28 | |
| YouTube | 17 | |
| Podcasts | 16 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 Positive
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Pharmacokinetics of Zolbetuximab; Gastric Cancer; Gastro-esophageal Junction (GEJ) Cancer; Pharmacokinetics of Oxaliplatin; Pharmacokinetics of Fluorouracil Bolus (5-FU)
- Interventions
- zolbetuximab; oxaliplatin; leucovorin; fluorouracil; Pembrolizumab; folinic acid; nivolumab; Docetaxel
- Arms
- zolbetuximab (Cohort 1A) · Experimental
- mFOLFOX6 plus zolbetuximab (Cohort 2) · Experimental
- Pembrolizumab plus zolbetuximab (Cohort 3A) · Experimental
- Zolbetuximab in combination with mFOLFOX6 and nivolumab (Cohort 4A/4B) · Experimental
- Zolbetuximab in combination with FLOT (Cohort 5) · Experimental
- Enrollment
- 143
- Primary outcomes
- Objective Response Rate (ORR) of zolbetuximab as a single agent by central review (Cohort 1)
- Sponsor
- Astellas Pharma Global Development, Inc.
- Start
- Jun 29, 2018
- Primary completion
- Jun 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03505320 · updated Aug 31, 2026
Publications
linked from the registry- Shitara K, Shoji H, Fazio N, Lonardi S, Lee KW, Bai LY, Yamaguchi K, Metges JP, Masi G, Smith D, Kim TY, Matsangou M, Shrivastava A, Zhou M, Hill J, Guerrero A, Wang X, Zaanan A, Klempner SJ. First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. 2026 Jun;32(6):2182-2190. doi: 10.1038/s41591-026-04306-9. Epub 2026 Mar 16. PubMed 41840238
- Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036. PubMed 40341124